Becton Dickinson and Company (NYSE:BDX) has announced its definitive agreement to acquire Parata Systems for $1.525 billion, a strategic move expected to close by the end of the first half of its fiscal year 2023. This acquisition follows a robust revenue report of $5.01 billion, surpassing estimates, and the company is prepared to post earnings of $2.52 per share. Despite challenging market conditions, BD stock has outperformed industry trends, gaining 4.48% year-to-date, prompting Morgan Stanley to raise its price target to $282 amid increasing confidence from investors.
“Becton Dickinson · reported · revenues · $5.01 billion”
“Becton Dickinson · is expected to post earnings · of $2.52 per share”
“Becton, Dickinson and Company · announced a definitive agreement for the former to acquire · Parata Systems · $1.525 billion”
“BD stock · has gained · 5.9% · over the past year”
“BD stock · has outperformed the industry’s decline of · 4.5%”
“BD stock · has outperformed the S&P 500's decline of · 5.2%”
“Becton, Dickinson and Company · announced a partnership with · CerTest Biotec”
“Becton, Dickinson and Company (NYSE:BDX) · manufactures · medical devices, reagents, and instrument systems”
“Becton, Dickinson and Company (NYSE:BDX) · announced its collaboration with · a European diagnostic device maker”
“49 hedge funds · were bullish on · Becton, Dickinson and Company (NYSE:BDX)”
“Morgan Stanley · lifted its price target on · Becton, Dickinson and Company (NYSE:BDX) · to $282”
“BD · is acquiring · Parata Systems · $1.525 billion”
%20logo.svg&width=160)